Poziotinib
As of the edition of 20 October 2026, Poziotinib is a small molecule: stopped in 2026; acts on EGFR, ERBB2 and ERBB3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 23, 9 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
7 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product7 company-target rows are on route A because of Poziotinib.
See the 7 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 0 | 1 |
| Phase 2 | 17 | 7 | 0 | 8 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hanmi Pharmaceutical | Lead sponsor of trials | 2009 to now |
| Zydus Worldwide DMCC | Lead sponsor of trials | 2016 to now |